Comparison of CAR-T19 and autologous stem cell transplantation for refractory/relapsed non-Hodgkin’s lymphoma

In a small clinical trial, CAR-T cell therapy exhibited superior clinical outcomes in safety and efficacy over autologous stem-cell transplantation in patients with relapsed/refractory non-Hodgkin’s lymphoma.

Saved in:
Bibliographic Details
Published in:JCI insight 2019-09, Vol.4 (17)
Main Authors: Li, Caixia, Zhang, Ying, Zhang, Changfeng, Chen, Jia, Lou, Xiaoyan, Chen, Xiaochen, Kang, Liqing, Xu, Nan, Li, Minghao, Tan, Jingwen, Sun, Xiuli, Zhou, Jin, Yang, Zhen, Zong, Xiangping, Wang, Pu, Xu, Ting, Qu, Changju, Huang, Haiwen, Jin, Zhengming, Yu, Lei, Wu, Depei
Format: Article
Language:English
Subjects:
Clinical Medicine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In a small clinical trial, CAR-T cell therapy exhibited superior clinical outcomes in safety and efficacy over autologous stem-cell transplantation in patients with relapsed/refractory non-Hodgkin’s lymphoma.
ISSN:2379-3708
2379-3708
DOI:10.1172/jci.insight.130195